ArticleJournal of controlled release : official journal of the Controlled Release Society2018
Investigation of tunable acetalated dextran microparticle platform to optimize M2e-based influenza vaccine efficacy.
Article in Journal of controlled release : official journal of the Controlled Release Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 70 citations in OpenAlex.
- Nanoparticle vaccine formulations for dengue virus.RSC pharmaceutics · 2026Review
- Biodegradable Polymers for Application as Robust Immunomodulatory Biomaterial Carrier Systems.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Optimizing delivery in a multivalent subunit influenza vaccine using mixed polymeric microparticle degradation rates.Journal of controlled release : official journal of the Controlled Release Society · 2025Article
- Modulating Adjuvant Release Kinetics From Scaffold Vaccines to Tune Adaptive Immune Responses.Advanced healthcare materials · 2025Article
- Impact and applications of cyclic di-GMP second messenger signaling in biotechnology and medicine.Sustainable microbiology · 2025Review
- Acetalated dextran: a novel delivery platform for particle-based vaccines.Expert opinion on drug delivery · 2025Article
- GFPBW1, a β-glucan from Grifola frondosa as vaccine adjuvant: APCs activation and maturation.Acta pharmacologica Sinica · 2024Article
- Comparison of emulsion and spray methods for fabrication of rapamycin-loaded acetalated dextran microparticles.RSC pharmaceutics · 2024Article
- Review
- Polymeric cGAMP microparticles affect the immunogenicity of a broadly active influenza mRNA lipid nanoparticle vaccine.Journal of controlled release : official journal of the Controlled Release Society · 2024Article
- Bis-2'-F-cGMolecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Comparative study of acetalated-dextran microparticle fabrication methods for a clinically translatable subunit-based influenza vaccine.International journal of pharmaceutics · 2024Article
- Immunogenicity of an adjuvanted broadly active influenza vaccine in immunocompromised and diverse populations.Bioengineering & translational medicine · 2024Article
- Recent Advances, Approaches and Challenges in the Development of Universal Influenza Vaccines.Influenza and other respiratory viruses · 2024Review
- COBRA Hemagglutinin and cGAMP Loaded Ace-DEX Microparticles Provide a Broadly Active and Shelf-Stable Influenza Vaccine Platform.Advanced therapeutics · 2024Article
- Dextran-based Drug Delivery Approaches for Lung Diseases: A Review.Current drug delivery · 2024Review
- Humoral Response to the Acetalated Dextran M2e Vaccine is Enhanced by Antigen Surface Conjugation.Bioconjugate chemistry · 2023Article
- Lymph Node Follicle-Targeting STING Agonist Nanoshells Enable Single-Shot M2e Vaccination for Broad and Durable Influenza Protection.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Natural Polymeric Composites Derived from Animals, Plants, and Microbes for Vaccine Delivery and Adjuvant Applications: A Review.Gels (Basel, Switzerland) · 2023Review
- Delivery of small molecule mast cell activators for West Nile Virus vaccination using acetalated dextran microparticles.International journal of pharmaceutics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Influenza places a significant health and economic burden on society. Efficacy of seasonal influenza vaccines can be suboptimal due to poor matching between vaccine and circulating viral strains. An influenza vaccine that is broadly protective against multiple virus strains would significantly improve vaccine efficacy. The highly conserved ectodomain of matrix protein 2 (M2e) and 3'3' cyclic GMP-AMP (cGAMP) were selected as the antigen and adjuvant, respectively, to develop the basis for a potential universal influenza vaccine. The magnitude and kinetics of adaptive immune responses can have great impact on vaccine efficacy. M2e and cGAMP were therefore formulated within acetalated dextran (Ace-DEX) microparticles (MPs) of varying degradation profiles to examine the effect of differential vaccine delivery on humoral, cellular, and protective immunity. All Ace-DEX MP vaccines containing M2e and cGAMP elicited potent humoral and cellular responses in vivo and offered substantial protection against a lethal influenza challenge, suggesting significant vaccine efficacy. Serum antibodies from Ace-DEX MP vaccinated mice also demonstrated cross reactivity against M2e sequences of various viral strains, which indicates the potential for broadly protective immunity. Of all the formulations tested, the slowest-degrading M2e or cGAMP MPs elicited the greatest antibody production, cellular response, and protection against a viral challenge. This indicated the importance of flexible control over antigen and adjuvant delivery. Overall, robust immune responses, cross reactivity against multiple viral strains, and tunable delivery profiles make the Ace-DEX MP platform a powerful subunit vaccine delivery system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.